期刊文献+

加替沙星眼用凝胶中微生物检查法的建立 被引量:6

Establishment of the method for microbial limit test of Gatifloxacin gel for eye
下载PDF
导出
摘要 目的完善加替沙星眼用凝胶微生物的限度检查方法。方法采用滤纸过滤(除去辅料)加薄膜过滤(过滤过程中加2%硫酸锰溶液的中和剂)法,去除主药加替沙星的抗菌活性。结果5株验证菌株中枯草芽孢杆菌对主药加替沙星最敏感,可作为加替沙星眼用凝胶微生物检查方法的质控菌株。结论所建方法可检查出眼用凝胶中的细菌、控制菌、霉菌及酵母菌。 OBJECTIVE To establish a method for microbial limit test of Gatifloxacin gel for Eye. METHODS Paper - filter ( removing excipients) and membrane - filter( adding 2% manganese sulfate solution in filtering course) method was first used to eliminate the antimicrobial activity of Gatifloxacin. RESULTS The method passed the validation test of Chinese Pharmacopoeia 2005 version. Bacillus subtilis was the most sensitive strain being recommended among the five validation strains, which was recommended for positive control in experiments. CONCLUSION The method for microbial limit test of Gatifloxacin gel for eye was : paper - filter and membrane -filter method, which was first used to bacteria, control bacteria (Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli), mold and yeasts.
出处 《华西药学杂志》 CAS CSCD 北大核心 2008年第6期701-703,共3页 West China Journal of Pharmaceutical Sciences
关键词 加替沙星眼用凝胶 滤纸过滤 薄膜过滤 中和剂 Gatifloxacin gel for eye Paper - filter Membrane - filter Neutralizer
  • 相关文献

参考文献3

二级参考文献17

  • 1张加玲,樊惠芝,潘景浩.电化学方法研究氟喹诺酮类药物与金属镁、锰离子的相互作用[J].山西临床医药,1996,5(4):311-314. 被引量:8
  • 2[1]Hosaka M,Yaxue T, Fukuda H, Tomizawa H, et al.In vitro and in vivo antibacterial activities of AM-1 155, a new 6-fluoro-8-methoxy quinolone. Antimicrobial Agents Chemotherapy, 1992;36:2108~2117.
  • 3[2]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methyoxy quinolone. Antimicrobial Agents Chemotherapy, 1994;38:594~601.
  • 4[3]Wise R, Brenwald NP, Andrews JM,et al. The activity of the methylpiperazinyl fluoroquinolone CG5501:A comparison with other fluoroquinolones fluoroquinolones. Antimicrobial Chemotherapy, 1997;39:447~452.
  • 5[4]National Committee for Clinical Laboratory Standards. 1998;18.
  • 6[5]Hosaka M,Kinoshita S, Toyama A,et al. Antibacterial Properties of AM-1155, a new 8-methoxy quinolone. Antimicrobial Chemotherapy, 1995; 36:293~301.
  • 7[6]Tanaka M,Takahashi K, Saika T, et al. Development of fluoroquinoloneresistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae in Japan. Urology, 1998; 159:2215~2219.
  • 8[7]Deguchi T, Yasuda M, Nakano M,ea al. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GryA and ParC.Chemotherapy, 1997;43:239~244.
  • 9[8]Nakashima M,Uematsu T,Kosuge K, et al. Single and multiple-dose pharmacolinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents Chemotherapy,1995;39:2635~2640.
  • 10ChP(中国药典).2005.Vol Ⅰ(一部):173

共引文献152

同被引文献36

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部